Details

Autor(en) / Beteiligte

• Prasad, Ananda S.
• Beck, Frances W. J.
• Bao, Bin
• Snell, Diane
• Fitzgerald, James T.

Titel

Duration and Severity of Symptoms and Levels of Plasma Interleukin-1 Receptor Antagonist, Soluble Tumor Necrosis Factor Receptor, and Adhesion Molecules in Patients with Common Cold Treated with Zinc Acetate

Ist Teil von

• The Journal of infectious diseases, 2008-03, Vol.197 (6), p.795-802

Ort / Verlag

Chicago, IL: The University of Chicago Press

Erscheinungsjahr

2008

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• BackgroundZinc lozenges have been used for treatment of the common cold; however, the results remain controversial MethodsFifty ambulatory volunteers were recruited within 24 h of developing symptoms of the common cold for a randomized, double-blind, placebo-controlled trial of zinc. Participants took 1 lozenge containing 13.3 mg of zinc (as zinc acetate) or placebo every 2–3 h while awake. The subjective scores for common cold symptoms were recorded daily. Plasma zinc, soluble interleukin (IL)–1 receptor antagonist (sIL-1ra), soluble tumor necrosis factor receptor 1, soluble vascular endothelial cell adhesion molecule, and soluble intercellular adhesion molecule (sICAM)–1 were assayed on days 1 and 5 ResultsCompared with the placebo group, the zinc group had a shorter mean overall duration of cold (4.0 vs. 7.1 days; P<.0001) and shorter durations of cough (2.1 vs. 5.0 days; P<.0001) and nasal discharge (3.0 vs. 4.5 days, P=.02). Blinding of subjects was adequate, and adverse effects were comparable in the 2 groups. Symptom severity scores were decreased significantly in the zinc group. Mean changes in plasma levels of zinc, sIL-1ra, and ICAM-1 differed significantly between groups ConclusionAdministration of zinc lozenges was associated with reduced duration and severity of cold symptoms. We related the improvement in cold symptoms to the antioxidant and anti-inflammatory properties of zinc